Welcome to our dedicated page for Painreform SEC filings (Ticker: PRFX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Monitoring how PainReform Ltd (PRFX) funds its PRF-110 extended-release ropivacaine program, navigates the FDA 505(b)(2) pathway, and manages clinical trial costs requires digging through dense biotech disclosures. Those SEC reports often exceed 200 pages, and finding the details that predict dilution risk or milestone timelines can feel impossible.
Stock Titan bridges that gap. Our AI-powered summaries turn every PainReform SEC filing into plain English, so “understanding PainReform SEC documents with AI” is no longer a wish. Our dedicated hub, “PainReform SEC filings explained simply,” ensures you grasp the essentials fast. Whether you need a PainReform quarterly earnings report 10-Q filing to gauge cash burn, or a PainReform 8-K material events explained alert to track trial readouts, we surface the numbers and material language instantly. Real-time PainReform Form 4 insider transactions show when executives buy or sell, while proxy statements reveal compensation aligned to PRF-110 milestones.
Still deciding which document matters? Here’s how investors use the page:
- PainReform annual report 10-K simplified – see R&D spend, liquidity runway, and expected regulatory milestones.
- PainReform earnings report filing analysis – compare quarter-over-quarter expenses and shares outstanding.
- PainReform insider trading Form 4 transactions – monitor management confidence before data releases.
- PainReform proxy statement executive compensation – understand how option grants are tied to FDA approvals.
Each document is tagged, searchable, and updated the moment it hits EDGAR, with PainReform Form 4 insider transactions real-time email alerts. Stop scrolling through legalese; our platform highlights key toxicity data, licensing agreements, and dilution clauses so you can act on facts, not speculation.
PainReform Ltd. reported that it has scheduled its Annual General Meeting of Shareholders for December 30, 2025, at 3:00 p.m. Israel time. The meeting will take place at the offices of the company’s legal counsel, Amit, Pollak, Matalon & Co., in Tel Aviv, Israel. To support the meeting, PainReform is providing a Notice and Proxy Statement and a Proxy Card for holders of ordinary shares so shareholders can review the agenda and vote their shares in advance or by proxy.
PainReform Ltd. (PRFX) furnished a Form 6-K noting it issued a press release on November 12, 2025 titled “PainReform’s DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset Analysis.” The release is attached as Exhibit 99.1 and incorporated by reference. The filing provides the exhibit index and signature by Ehud Geller, Executive Chairman and Interim Chief Executive Officer.
PainReform Ltd. (PRFX) filed a Form 6-K noting it issued a press release on November 5, 2025 titled “PainReform’s DeepSolar, Developing ‘DeepSolar Predict’ within the NVIDIA Connect Program, Featured in The Market Link’s ‘Watchlist Interview’ and Announces Progress Toward Pilot Projects.” The press release is attached as Exhibit 99.1 and incorporated by reference.
The report is signed by Ehud Geller, Executive Chairman of the Board and Interim Chief Executive Officer.
PainReform Ltd. filed a Form 6-K reporting that on October 1, 2025 it issued a press release announcing its financial results for the six months ended June 30, 2025 and furnished unaudited condensed financial statements and an operating and financial review for that period.
The filing also discloses a board change: Professor Eli Hazum resigned effective September 30, 2025 for personal reasons, expressly not due to any disagreement with management, and Asaf Shavit was appointed to the Board effective immediately; Mr. Shavit is a Certified Public Accountant with 35+ years of audit, tax and financial advisory experience.
PainReform Ltd. completed a strategic investment in LayerBio to enter the global cataract surgery market, described in the filing as a $9 billion opportunity, via a non-opiate, non-steroidal postoperative NSAID drug delivery system. The report attaches the press release as Exhibit 99.1 and states the first paragraph of that release is incorporated by reference into the company’s Form S-8 and Form F-3 registration statements.
The filing is a disclosure of the investment and the attached press release; it does not provide financial terms, clinical data, or operational results within the text of the Form 6-K itself.
FAQ
What is the current stock price of Painreform (PRFX)?
What is the market cap of Painreform (PRFX)?
